The kinase inhibitor ENMD-2076 may effectively target the p53 family of tumor suppressors, which have been connected to triple-negative breast cancer (TNBC), according to results of a phase II clinical study. Data demonstrate that ENMD-2076 exhibited “robust anticancer activity” against both p53 and p73 mutations, said chief researcher Jennifer R. Diamond. M.D., of the University of Colorado. Research is being conducted by the drug company EntreMed in patients with TNBC and advanced/metastatic soft tissue sarcoma. The next step, before the drug could be generally available, would be a phase III clinical trial.
• Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.